Ozempic and Mounjaro Linked to Rare Eye Disorder, Australian 2026

Australia's medicines regulator has issued a warning that Ozempic and other GLP-1 drugs may be linked to a rare but severe eye disorder called non-arteritic anterior ischaemic optic neuropathy (NAION), which can lead to blindness. The Therapeutic Goods Administration (TGA) reported 36 cases of NAION associated with these medications, including Ozempic, Wegovy, and Mounjaro.

What Is NAION and How Is It Linked to Ozempic?

NAION is a condition that causes sudden vision loss due to reduced blood flow to the optic nerve. The TGA states that once NAION develops, no treatment has been shown to improve visual outcomes. Product information for Australians has been updated to reflect this risk.

Patients are urged to seek urgent medical attention if they experience any sudden vision changes, including partial loss of sight. However, the TGA does not recommend stopping treatment without consulting a doctor, nor has it placed new prescription restrictions.

Expert Perspective on the Risk

Professor Helen Danesh-Meyer from the Royal Australian and New Zealand College of Ophthalmologists emphasized that NAION is “a very rare condition” that needs to be put in perspective. She noted that while blindness is a serious concern, the medications treat common life-threatening conditions such as heart attacks, stroke, and kidney disease.

“If it helps manage and prevent those life-threatening risks, then for that patient it is probably better to continue it,” she said.

Key Data on GLP-1 Drugs and NAION Cases

Key Takeaways for Patients

• Know the symptoms: Sudden vision loss or partial vision loss requires immediate medical attention.
• Do not stop medication abruptly: Always consult your doctor before making changes to your treatment.
• Understand the rarity: NAION remains very rare; the benefits of GLP-1 drugs often outweigh the risks.
• Stay informed: The TGA continues to monitor the link and update product information.

Frequently Asked Questions

The TGA first became aware of the potential link in 2024 following a peer-reviewed study. Since then, the regulator has closely monitored evidence and conducted an independent assessment of the association. For the latest updates, Australians are encouraged to consult their healthcare provider and review updated product information.